0000899243-17-018236.txt : 20170713 0000899243-17-018236.hdr.sgml : 20170713 20170713170957 ACCESSION NUMBER: 0000899243-17-018236 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170712 FILED AS OF DATE: 20170713 DATE AS OF CHANGE: 20170713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: WAVE Life Sciences Ltd. CENTRAL INDEX KEY: 0001631574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 CROSS STREET STREET 2: #10-00 CITY: SINGAPORE STATE: U0 ZIP: 048424 BUSINESS PHONE: 617-206-4830 MAIL ADDRESS: STREET 1: 8 CROSS STREET STREET 2: #10-00 CITY: SINGAPORE STATE: U0 ZIP: 048424 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences Ltd. DATE OF NAME CHANGE: 20151106 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences LTD. DATE OF NAME CHANGE: 20151106 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences Pte Ltd DATE OF NAME CHANGE: 20150123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Panzara Michael A. CENTRAL INDEX KEY: 0001679039 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37627 FILM NUMBER: 17964062 MAIL ADDRESS: STREET 1: 733 CONCORD AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02138 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-07-12 0 0001631574 WAVE Life Sciences Ltd. WVE 0001679039 Panzara Michael A. C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE. CAMBRIDGE MA 02138 0 1 0 0 Franchise Lead, Neurology Ordinary Shares 2017-07-12 4 S 0 7414 16.6738 D 15336 D On July 12, 2017, the reporting person sold 7,414 ordinary shares solely to cover taxes associated with the vesting of restricted share units on July 11, 2017. These sales were made pursuant to a 10b5-1 Trading Plan entered into solely for the purpose described in the prior sentence. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.55 to $16.95 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. /s/ Michael A. Panzara 2017-07-13